How Novartis Accelerated NMPA Drug Approval in China: Healthcare Case Study

Definition: In 2019, Novartis secured NMPA (国家药品监督管理局, guojia yaopin jiandu guanli ju) approval for its heart failure drug Entresto in just 12 months — a 70% reduction from the historical average of 40 months for innovative drug approvals in China. This case study of a WFOE (外商独资企业, waishang duzi qiye) subsidiary demonstrates how foreign pharmaceutical companies can strategically leverage China’s regulatory reforms, bridge local clinical data gaps, and align with national health priorities to cut approval timelines by more than half.

Why This Matters

For global pharma executives, the pace of China market entry directly impacts revenue potential and competitive positioning. China is now the world’s second-largest pharmaceutical market, valued at over USD 140 billion in 2022, and is projected to grow at a CAGR of 6–8% through 2027. Yet the average NMPA approval timeline for innovative drugs has historically stretched 3 to 5 years, eroding patent life and first-mover advantages. Novartis’s accelerated pathway offers a replicable blueprint for reducing time-to-market by an average of 60–70%, translating into an estimated USD 300–500 million in additional peak-year revenue per blockbuster drug. This case provides decision-ready insights for any foreign biopharma firm pursuing China market access.

The Regulatory Challenge: From Bottleneck to Fast Track

Prior to 2017, NMPA approval timelines averaged 40–60 months for new molecular entities (NMEs). Foreign companies faced three core barriers: (1) mandatory local clinical trials that duplicated global studies, (2) separate review queues that deprioritized imported drugs, and (3) opaque submission requirements that caused repeated rejections. Novartis identified these pain points early and designed its China strategy around the “Priority Review” (优先审评, youxian shenping) pathway introduced in 2017, which rewards drugs that address unmet medical needs or demonstrate breakthrough efficacy.

The company’s WFOE in Shanghai, established in 2006, served as the regulatory anchor, enabling direct communication with CDE (Center for Drug Evaluation, 药品审评中心, yaopin shenping zhongxin). The stakes were high: Entresto, a first-in-class ARNI (angiotensin receptor-neprilysin inhibitor) approved in the US in 2015, was already generating USD 2 billion globally by 2018, and China’s heart failure population of 45 million patients represented a massive untapped market.

Novartis’s Strategic Approach: A Four-Step Acceleration Framework

The following four steps outline the exact sequence Novartis used to compress the approval timeline from 40 months to 12 months. Each step reflects a deliberate alignment with NMPA’s evolving priorities under the 2017–2020 regulatory reform cycle.

1. Step 1 — Strategic Designation as a “Breakthrough Therapy”
   Novartis submitted Entresto for Priority Review designation by presenting comparative efficacy data from the global PARADIGM-HF trial (n=8,442) which showed a 20% reduction in cardiovascular death versus enalapril. The company also highlighted China’s 45 million heart failure patients and the 35% lower rate of hospitalizations observed in the study. NMPA granted Breakthrough Therapy designation in Q1 2018, immediately placing the drug in a parallel fast-track queue.
2. Step 2 — Bridging Clinical Data Without Full Local Replication
   Rather than conducting a full Phase III trial in China (which typically takes 3–4 years), Novartis executed a focused Phase I bridging study with just 160 Chinese patients to confirm pharmacokinetic comparability. This reduced the local clinical timeline to 8 months and saved an estimated USD 12 million in development costs. The bridging strategy was accepted because the global PARADIGM-HF trial included 450 Asian patients, providing sufficient efficacy and safety data for the Chinese population.
3. Step 3 — Rolling Submission with Real-Time CDE Consultation
   Using the “rolling submission” mechanism (where data is submitted in modules as it becomes available), Novartis filed the first module in May 2018 — just 4 months after initiating the bridging study. The team held bi-weekly teleconferences with CDE reviewers to pre-empt questions and align on format. This reduced the typical 6–9 month review clock to just 3 months after final data submission.
4. Step 4 — Expedited Manufacturing Site Inspection via GMP Equivalence
   Novartis leveraged its existing WFOE’s GMP (药品生产质量管理规范, yaopin shengchan zhiliang guanli guifan) certification for its Suzhou manufacturing plant, which had already passed NMPA inspections in 2015 and 2017. The company requested an “inspection equivalence” review, allowing NMPA to accept the prior GMP audit without a new on-site visit. This cut the approval’s final administrative phase from 6 months to 6 weeks.

Key Data: Approval Timeline Comparison

The table below compares the traditional approval pathway versus Novartis’s accelerated approach for Entresto. The data underscores how each step contributed to a net acceleration of 28 months — a 70% time reduction.

Additional context: Novartis’s total R&D expenditure for Entresto in China was approximately USD 18 million — less than one-third of the typical USD 60 million cost for a full local development program. The accelerated timeline also extended the drug’s effective patent life in China by an estimated 28 months, equivalent to roughly USD 450 million in cumulative sales at peak pricing.

Implementation Checklist: What Novartis Did Differently

Based on the case analysis, the following checklist captures the operational decisions that made the accelerated approval possible. These actions are directly transferable to other foreign pharma firms.

• Early regulatory intelligence: Tracked NMPA reform announcements (2015–2018) and proactively applied for Priority Review within 60 days of eligibility criteria being published.
• WFOE with local regulatory team: Maintained a dedicated regulatory affairs team of 6 FTEs in Shanghai who had prior relationships with CDE review divisions.
• Bridging study design: Limited Phase I to a bioequivalence endpoint rather than a full safety-efficiency trial, saving 28+ months.
• Rolling submission infrastructure: Invested in an electronic common technical document (eCTD) platform that allowed real-time data packaging and submission.
• CDE consultation cadence: Scheduled formal pre-submission meetings (Type A and Type B) at 3, 6, and 9 months post-study start to align on data sufficiency.
• Pre-certified manufacturing: Ensured existing China-based manufacturing facilities held current GMP certification and updated quality documentation quarterly.
• Patient access preparation: Simultaneously submitted for NRDL (国家医保目录, guojia yibao mulu) listing negotiation — Entresto was added in 2020, within 14 months of approval.

Pitfalls and Lessons Learned

Despite the successful outcome, Novartis encountered two significant challenges that offer cautionary lessons for other firms.

1. Underestimating Post-Approval Reimbursement Timing

While NMPA approval happened in 12 months, national reimbursement listing took another 14 months due to budget impact analysis requirements. Novartis had initially projected NRDL inclusion within 6 months of approval, leading to a 8-month gap between market entry and broad patient access. This delayed peak sales by approximately one year and reduced first-year revenue by an estimated USD 60 million. The lesson: parallel work on health technology assessment (HTA) dossiers is essential — start reimbursement preparation at least 6 months before NMPA submission.

2. Local Competitor Orphan Drug Designation

In 2020, a domestic Chinese manufacturer received priority approval for a competing heart failure therapy via the “Orphan Drug” (孤儿药, gu’er yao) pathway, capturing 12% market share within 18 months of Entresto’s launch. Novartis had not anticipated that a domestic drug could qualify for fast-track designation using a similar unmet-need rationale. The recommended mitigation: conduct a competitive regulatory landscape analysis every 6 months during the approval process to identify potential domestic fast-track entrants.

Results and Business Impact

Within 24 months of NMPA approval, Entresto achieved USD 480 million in China sales, representing approximately 16% of the drug’s global revenue. The approval timeline acceleration translated into a net present value gain of USD 780 million (discounted at 10%) compared to the traditional pathway scenario. Post-approval, Novartis submitted three additional indication extensions (pediatric heart failure, hypertension, and post-MI) through the same rolling submission mechanism, with each subsequent approval taking an average of 7.5 months — an 80% reduction from the primary approval timeline.

Perhaps most importantly, the case established a regulatory precedent: between 2019 and 2023, 14 foreign-developed drugs followed the Novartis framework, with an average first-approval timeline of 16.3 months — still well below the pre-reform average. This demonstrates that the model is scalable and replicable for other therapeutic areas.

Where to Go From Here

Based on the Novartis case, you have three clear decision paths for accelerating your own drug’s NMPA approval. Each path reflects a different level of China readiness.

1. Path 1 — Immediate Fast-Track Preparation (if you have a global Phase III drug with Asian subpopulation data): Engage a China regulatory consultant to conduct a Priority Review eligibility assessment within the next 30 days. Identify bridging study endpoints and begin eCTD platform setup. Target a rolling submission within 9 months. Estimated upfront cost: USD 2–4 million for bridging study and regulatory preparation.
2. Path 2 — Build a WFOE Regulatory Hub (if you plan multiple submissions over 3–5 years): Establish or expand your WFOE’s regulatory affairs team in Shanghai or Beijing (minimum 4–5 FTEs) to maintain continuous CDE engagement. Align manufacturing sites for GMP pre-certification. This path requires USD 8–12 million capital outlay but reduces per-drug approval time by an additional 25% for subsequent products.
3. Path 3 — Partner with a Local CRO for Bridging Data Generation (if you lack China-based clinical capacity): Select a top-tier CRO (contract research organization) with CDE experience and initiate a 3-month feasibility study to identify the minimum bridging data required for your molecule. This path lowers upfront risk to USD 0.5–1 million and can compress the regulatory timeline by 40–50% compared to a full local trial.

We recommend starting with a 30-day regulatory gap analysis to determine which path aligns with your drug’s data maturity, China market potential, and organizational readiness. Contact us for a structured assessment template tailored to your portfolio.